Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008

HIV Medicine

Volumn 12, Issue 3, 2011, Pages 174-182

  Prosperi, M C F ^a   Cozzi Lepri, A ^b   Antinori, A ^c   Cassola, G ^d   Torti, C ^e   Ursitti, M A ^f   Pellizzer, G P ^g   Giacometti, A ^h   D'Arminio Monforte, A ⁱ   De Luca, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

^f Reggio Emilia Hospital   (Italy)

^g Hospital of Vicenza   (Italy)

^h UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

HIV 1; Immunological response rates; Poisson regression; Virological response rates

Indexed keywords

VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; FEMALE; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; ITALY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; ITALY; MALE; POISSON DISTRIBUTION; PREVALENCE; SEXUAL BEHAVIOR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79551595138     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00866.x     Document Type: Article

References (25)

1. Mocroft A, Katlama C, Johnson AM et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356: 291-296.
2. Martin JC, Soriano V, Jimenez-Nacher I, Martinez P, Gonzalez-Lahoz J. Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies. Clin Microbiol Infect 2001; 7: 678-681.
3. Sabin CA, Hill T, Lampe F et al. for the UK Collaborative HIV Cohort (UK CHIC) Study Group. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005; 330: 695-698.
4. Kirk O, Mocroft A, Katzenstein TL et al. for the EuroSIDA Study Group. Changes in use of antiretroviral therapy in regions of Europe over time. AIDS 1998; 12: 2031-2039.
5. Egger M, May M, Chêne G et al. for the ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129. Erratum in: Lancet 2002; 360: 1178.
6. Madge S, Smith CJ, Lampe F et al. An audit of viral load in one clinical population to describe features of viraemic patients on antiretroviral therapy. HIV Med 2008; 9: 208-213.
7. Bannister WP, Ruiz L, Loveday C et al. for the EuroSIDA Study Group. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antiviral Ther 2006; 11: 707-715.
8. Saul J, Erwin J, Bruce JC, Peters B. Ethnic and demographic variations in HIV/AIDS presentation at two London referral centres 1995-9. Sex Transm Infect 2000; 76: 215.
9. Soriano V, Mocroft A, Rockstroh J et al. for the EuroSIDA Study Group. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008; 198: 1337-1344.
10. Gilson RJ, Hawkins AE, Beecham MR et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997; 11: 597-606.
11. Sinicco A, Raiteri R, Sciandra M et al. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. Scand J Infect Dis 1997; 29: 111-115.
12. Dorrucci M, Pezzotti P, Phillips AN, Cozzi-Lepri A, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 1995; 172: 1503-1508.
13. Lampe FC, Smith CJ, Madge S et al. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007; 167: 692-700.
14. Suligoi B, Pezzotti P, Boros S, Urciuoli R, Rezza G. HIV Study Group Epidemiological changes in AIDS and HIV infection in Italy. Scand J Infect Dis Suppl 2003; 35 (Suppl 106): 12-16.
15. Pezzotti P, Dorrucci M, Donisi A et al. Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART). Epidemiol Prev 2003; 27: 348-355.
16. Ammassari A, Trotta MP, Murri R et al. for the AdICoNA Study Group. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002; 31 (Suppl 3): S123-S127.
17. Murri R, Ammassari A, Trotta MP et al. for the AdICoNA Study Group. Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med 2004; 19: 1104-1110.
18. Vo TT, Ledergerber B, Keiser O et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008; 197: 1685-1694.
19. Available at
20. Chambers JM, Hastie TJ. Statistical Models in S. Pacific Grove, CA: Wadsworth and Brooks/Cole Advanced Books and Software, 1992.
21. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
22. Prentice RL, Zhao LP. Estimating equations for parameters in means and covariances of multivariate discrete and continuous responses. Biometrics 1991; 47: 825-839.
23. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2008. ISBN 3-900051-07-0. Available at (accessed 25 June 2010).
24. Walker BD. Elite control of HIV Infection: implications for vaccines and treatment. Top HIV Med 2007; 15: 134-136.
25. Pezzotti P, Phillips AN, Dorrucci M et al. Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. BMJ 1996; 313: 583-586.